Syndax Pharmaceuticals director Dennis Podlesak sells $113,716 in stock
What it means
- What to watch: The headline hangs on one number ($113,716) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $SNDX -3.53% in the latest session.
- Timing: Filed after the close: the price beside it finished its day before the story existed, so the next session gets the first real vote.
Where the stock stands
$SNDX last traded at $13.65, -3.53% on the session. That puts it 47% shy of its 52-week high of $25.59 and 6.7% clear of its low of $12.80 — within a tenth of its 52-week low. Over the year it has ranged 100% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $SNDX page.
How much coverage it is getting
In the last 30 days Wook has filed 3 stories about $SNDX — 1 of them this week. At its 30-day pace you would expect about 1 a week, so this week is somewhat busier than usual. Across those stories 0 read bullish, 2 neutral and 1 bearish. This one reads neutral, so it sits squarely with the crowd. 2 of the 3 (67%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$SNDX earnings in 2 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
The $SNDX page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $SNDX is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $SNDX. It carried $113,716, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.